[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2023128898A1 - Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients - Google Patents

Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients Download PDF

Info

Publication number
WO2023128898A1
WO2023128898A1 PCT/TR2021/051618 TR2021051618W WO2023128898A1 WO 2023128898 A1 WO2023128898 A1 WO 2023128898A1 TR 2021051618 W TR2021051618 W TR 2021051618W WO 2023128898 A1 WO2023128898 A1 WO 2023128898A1
Authority
WO
WIPO (PCT)
Prior art keywords
macitentan
tablet
binder
disintegrant
pharmaceutical composition
Prior art date
Application number
PCT/TR2021/051618
Other languages
French (fr)
Inventor
Abdulhaluk SANCAK
Ayse Figen ONUK GOREN
Hakan GURPINAR
Asiye Sezgin
Azmatullah ANSARI
Gizem ALKAN
Koray YILMAZ
Original Assignee
Humanis Saglik Anonim Sirketi
Adalvo Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humanis Saglik Anonim Sirketi, Adalvo Limited filed Critical Humanis Saglik Anonim Sirketi
Priority to EP21970145.5A priority Critical patent/EP4456983A1/en
Priority to PCT/TR2021/051618 priority patent/WO2023128898A1/en
Publication of WO2023128898A1 publication Critical patent/WO2023128898A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to the preparation of pharmaceutical compositions comprising macitentan is indicated for the treatment of pulmonary arterial hypertension (PAH), having a specific ratio of binder to disintegrant in formulation.
  • PAH pulmonary arterial hypertension
  • Macitentan has a chemical name as 5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2- yl)oxyethoxy]-N-(propylsulfamoyl)pyrimidin-4-amine and its chemical structure is shown in the Figure I. Macitentan has molecular weight of 588,3 g/mol, white or off-white Solid, crystalline powder.
  • Macitentan has been used as an orphan drug in the EU with the name of Opsumit and also in United States, is indicated for patients with pulmonary arterial hypertension.
  • Pulmonary arterial hypertension is a condition where there is high blood pressure in the arteries that supply the lungs. Pulmonary arterial hypertension (PAH) is also associated with a number of other medical diseases such as cirrhosis and connective tissue diseases like scleroderma.
  • EP1928409B relates to a pharmaceutical composition
  • a pharmaceutical composition comprising macitentan and specific formulation excipients with lactose monohydrate, microcrystalline cellulose, polyvinylpyrrolidone, sodium starch glycolate, a surfactant (polysorbate) and a lubricant.
  • a pharmaceutical composition may comprise one or more pharmaceutically acceptable excipient(s).
  • Pharmaceutically acceptable excipients examples can be filler, disintegrant, binder, surfactant, lubricant, solvent, antiadherent, flavor, glidant, preservative, sweetener, suspending/viscosity agent, diluent, colorant and the mixtures thereof.
  • Ideal pharmaceutical excipient profile should have suitable physical and chemical properties with active ingredient and also other raw materials. These properties can be stable and reproducible, no unwanted interaction with active ingredient, inert property, desired functionality and cost effective.
  • Binder in a pharmaceutical composition is binder in a pharmaceutical composition. Binders can be used for tablets that can provide the required mechanical strength, and also volume for low active dose tablets.
  • Disintegrating agents are the substances which are added to an oral solid dosage to promote its rapid disintegration or break down into small particles after administration for facilitating rapid dissolution. Disintegrating agents are added to an oral solid dosage form to get quick drug release. Disintegrants are used to control the disintegration time for oral solid dosage forms such as tablets, capsules and the others as per pharmacopoeia.
  • Disintegrants can be classified into two groups, traditional and Super Disintegrants. Examples for traditional disintegrants: starch, sodium alginate etc. Examples for Super Disintegrants: crospovidone, croscarmellose sodium, sodium starch glycolate etc.
  • the present invention relates to the preparation of pharmaceutical compositions comprising macitentan, and one or more pharmaceutically acceptable excipients comprising a binder and a disintegrant with a specific ratio.
  • a pharmaceutical composition comprising macitentan or pharmaceutically acceptable salts thereof, a disintegrant, a binder and optionally one or more pharmaceutically acceptable excipients, wherein the weight ratio of the binder to the disintegrant is from 0,55 to 0,72.
  • the present invention relates to preperation of pharmaceutical compositions comprising macitentan in the treatment of pulmonary arterial hypertension.
  • the present invention provides a pharmaceutical composition comprising macitentan for the treatment of pulmonary arterial hypertension, wherein process including wet granulation method.
  • the present invention relates to the preparation of pharmaceutical compositions comprising macitentan or pharmaceutically acceptable salts or esters thereof, and one or more pharmaceutically acceptable carriers or excipients.
  • the present invention relates to the preparation of pharmaceutical compositions comprising macitentan, and one or more pharmaceutically acceptable carriers or excipients, comprising a binder and a disintegrant with a specific weight ratio.
  • the present invention relates to the preperation of pharmaceutical compositions comprising macitentan, and one or more pharmaceutically acceptable carriers or excipients, including a binder with a specific interval by tablet weight.
  • the present invention relates to the preperation of pharmaceutical compositions comprising macitentan, and one or more pharmaceutically acceptable carriers or excipients, including a disintegrant with a specific interval by tablet weight.
  • a pharmaceutical composition comprising macitentan or pharmaceutically acceptable salts thereof, a disintegrant, a binder and optionally one or more pharmaceutically acceptable excipients, wherein the weight ratio of the binder to the disintegrant is from 0,55 to 0,72.
  • compositions comprising macitentan and a disintegrant selected from a list consisting of: crospovidone, sodium starch glycolate and croscarmellose sodium or mixture thereof.
  • compositions comprising macitentan and a disintegrant at a concentration of from 2% to 4% (w/w).
  • compositions comprising macitentan and a binder having a concentration of from 1% to 3% (w/w).
  • the pharmaceutical composition can be in the form of a tablet.
  • target properties of tablet dosage forms is below:
  • ⁇ Tablet should have elegant product without any cracks, discoloration or contamination.
  • ⁇ Tablet form should have predictable and reproducible manner for releasing the active ingredients.
  • physicomechanical properties are determined such as particle size, tap density, crystalline form, compressibility, photomicrographs, melting point, taste, color, appearance, and viscosity. These properties has an important role in powder flow and compaction in tablet manufacturing process.
  • Dissolution test values for pharmaceutical compositions are one of the essential parameters for process development and solid dosage manufacturing.
  • excipients that is used in tablet dosage form are diluent, binder, disintegrants, lubricant, glidant, colouring agent, flavoring agent, sweetening agent and solvent except active ingredient.
  • compositions comprising macitentan and a disintegrant at a concentration of from 2% to 4% (w/w).
  • the ratio of disintegrants used to tablet weight is between 2%-4%.
  • the composition comprises a disintegrant at the concentration of 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.4, 3.6, 3.8 and 4.0% (w/w). The most preferred amount in this range is 3.0%.
  • the ratio of binder used to the total weight is between 1% - 3%.
  • the composition comprises binder at the concentration of 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, 2.6, 2.8 and 3.0% (w/w). The most preferred amount in this range is 2.0%.
  • manufacturing process generally consisting of four stages: a) Sieving and mixing, b) Wet Granulation, c) Mixing granule with external excipients, d) Tablet compression and Film Coating.
  • the amount of coating material by weight will be from 2 to 6%, preferably from 3 to 5% and more preferably from 3.5 to 4.5% of the weight of the tablet before its coating.
  • disintegrant and binder are very critical. Disintegrant and binder should be selected with given ratio and properties.
  • Table 1 Comparison table for relevant excipients of Macitentan lOmg Tablet (Test product), excipients on EP 1928409 examples and excipients of Opsumit product in Russia market.
  • the main point is that the weight ratio of the binder to disintegrant in tablet composition comprising macitentan.
  • the stability of the pharmaceutical composition may be tested in conventional manner, e.g. by measurement of macitentan and its degradation products, dissolution, friability, disintegration time, appearance and/or microscopy, e.g. after storage at 25 °C and 60% relative humidity, and/or storage at 40°C and 75% relative humidity for defined periods of time.
  • the formulations preferably contain active ingredient, filler, disintegrant, binder, surfactant, lubricant and solvent.
  • tablets may also be produced.
  • the tablets may vary in shape and be, for example, round, oval, oblong, cylindrical, clover-shaped or any other suitable shape.
  • w/w% refers to a percentage by weight compared to the total weight of the composition considered.
  • a pharmaceutical composition according to the invention is considered “stable”, if during a certain period of time 70%, preferably 80% and most preferably 95% of the initial content of macitentan, is maintained over said period of time.
  • treatment means any treatment of a disease or condition in a subject, such as a mammal, including: 1) preventing or protecting against the disease or condition, that is, causing the clinical symptoms not to develop; 2) inhibiting the disease or condition, that is, arresting or suppressing the development of clinical symptoms; and/or 3) relieving the disease or condition that is, causing the regression of clinical symptoms.
  • pulmonary hypertension will be understood to include “a condition where there is high blood pressure in the arteries that supply the lungs”, including Subdivisions of Pulmonary Arterial Hypertension and World Health Organization classifications for Pulmonary Hypertension (PH).
  • wet granulation is the most widely used process of granulation in the pharmaceutical industry. Wet granulation process can be very simple or very complex depending on the characteristics of the powders and the available equipments.
  • wet granulation method involves addition of a liquid solution (with or without binder) to powders, to form a wet mass or it forms granules by adding the powder together with an adhesive, instead of by compaction. Then, drying process starts and then sized to obtained granules with desired mesh. The granulate may then be tabletted /compressed, or other excipients may be added prior to tableting with suitable excipients.
  • oral solid dosage form denotes solid preparations (e.g. tablets) for oral administration each containing a single dose of one or more active substances.
  • composition of the present inventions may comprise one or more pharmaceutically acceptable excipient(s).
  • Pharmaceutically acceptable excipients comprise, but are not limited to, filler, disintegrant, binder, surfactant, lubricant, solvent and the mixtures thereof, to facilitate the physical formulation of various dosage forms for oral administration like tablets.
  • “pharmaceutically acceptable salt” refers to a salt of a compound that does not abrogate the biological activity and properties ofthe compound.
  • Pharmaceutical salts can be obtained by reaction of a compound disclosed herein with an acid or base.
  • Suitable disintegrants according to the present invention include, but are not limited to, carboxymethylcellulose calcium, carboxymethylcellulose sodium, croscarmellose (crosslinked carboxymethylcellulose) sodium, cross-linked polyvinylpyrrolidone, crospovidone (crosslinked povidone, a synthetic cross-linked homopolymer of N-vinyl-2-pyrrolidone), alginic acid, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, polacrillin potassium, sodium alginate, sodium starch glycolate, partially hydrolysed starch, sodium carboxymethyl starch, and starch.
  • the preferred disintegrant is crospovidone.
  • Suitable binders according to the present invention include, but are not limited to, hydroxypropyl cellulose, hypromellose (hydroxypropyl methylcellulose, HPMC), HPMC E5, acacia, alginic acid, carboxymethylcellulose, methylcellulose, hydroxyethylcellulose, ethylhydroxyethylcellulose, carboxymethylcellulose sodium, methylcellulose, polyvinyl pyrrolidone and pregelatinized starch.
  • the preferred binder is Povidon K30.
  • Suitable lubricants according to the present invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, stearic acid, fumaric acid, sodium stearylfumarate, zinc stearate and polyethylene glycol.
  • the preferred lubricant is magnesium stearate.
  • Suitable fillers according to the present invention include, but are not limited to, dibasic calcium phosphate, kaolin, microcrystalline cellulose, silicated microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, magnesium trisilicate, lactose such as example the anhydrous form or the hydrate form such as the monohydrate form, sugars such as dextrose, maltose, saccharose, glucose, fructose or maltodextrine, sugar alcohols such as mannitol, maltitol, sorbitol, xylitol, powdered cellulose, precipitated calcium carbonate, sodium carbonate, sodium phosphate and starch. Fillers which are slightly hygroscopic or non- hygroscopic are preferred, with non-hygroscopic fillers being particularly preferred, in particular when the dosage form is to be used for tropical countries.
  • the preferred filler is microcrystalline cellulose.
  • Suitable surfactants and wetting agents include, but are not limited to, heptadecaethylene oxycetanol, lecithins, sorbitol monooleate, polyoxyethylene sorbitol monooleate, polyoxyethylene stearate, polyoxyethylen sorbitan monolaurate, benzalkonium chloride, nonoxynol 10, oxtoxynol 9, polysorbates, for example polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 80, sorbitan monopalmitate, sodium salts of fatty alcoholsulfates such as sodium lauryl sulfate, sodium dodecylsulfate, sodium salts of sulfosuccinates such as sodium dioctylsulfosuccinate, partially esters of fatty acids with alcohols such as glycerine monostearate, partially esters of fatty acids with sorbitans such as sorbitan monolaurate,
  • Suitable film-forming agents and coating materials according to the present invention include, but are not limited to, liquid glucose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (hypromellose, HPMC), methylcellulose, ethylcellulose, cellulose acetate phthalate, shellac, polyvinylpyrrolidone, copolymers of vinylpyrrolidone and vinylacetate such as Kollidon® VA64 BASF, copolymers of acrylic and/or methacrylic acid esters with trimethylammoniummethylacrylate, copolymers of dimethylaminomethacrylic acid and neutral methacrylic acid esters, polymers of methacrylic acid or methacrylic acid esters, copolymers of acrylic acid ethylester and methacrylic acid methyl ester, and copolymers of acrylic acid and acrylic acid methylester.
  • liquid glucose hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl
  • Solvents can be selected from the group, but not limited to, ethanol, ethyl alcohol, polyethylene glycol, propylene glycol, isopropyl alcohol, purified water and other materials known to one of ordinary skill in the art and mixtures thereof.
  • the preferred solvent is purified water.
  • compositions of the invention are particularly suited for the oral administration.
  • compositions of the invention are particularly shows similar property in the stability and dissolution, it is extremely useful as a pharmaceutical product preparation technique.
  • the present invention provides pharmaceutical composition comprising macitentan and relevant excipients, characterized by i) A simple and exclusive manufacturing process ii) Stable formulation
  • Tablet dosage form is simple, cost-effective, easy and convenient to use, so it has high patient compliance.
  • compositions of the invention are advantageously in the form of unit dose.
  • each unit dose according to the invention comprises 1 to 100 mg, e.g. 5 to 50 mg, advantageously 8 to 20 mg, e.g. about 10 mg according to the invention, advantageously in combination with standard excipients and additives well known to one skilled in the field.
  • tablet containing a binder shows similar dissolution property and by the addition of it, the drug dissolution property could be easily controlled.
  • Table 2 Summary of Batches used in In Vitro Dissolution Tests In this invention, the dissolution test has been performed for Opsumit 10 mg FTB and Macitentan 10 mg Tablet (Test Product) pH 1.2 with 0,1 HCL + % 0,1 CT AB. It is shown in Table 3 and Figure 1. Drug release for both the test product and the reference product were found to be satisfactory.
  • Table 3 Summary of Dissolution Results of Macitentan 10 mg Film tablet (Test Product) in Comparison to Opsumit 10 mg FTB (Reference Product) in pH 1.2 with 0,1 HCL + 0,1% CTAB.
  • Figure 1 Comparative Dissolution Profiles of Opsumit 10 mg Film Tablet and Macitentan 10 mg Film Tablet (Test Product) pH 1.2 with 0,1 HCL + 0,1% CTAB.
  • the dissolution test has been performed for Opsumit 10 mg Film Tablet and Macitentan 10 mg Film Tablet (Test Product) in acetat buffer pH 4.5 with 0.1% CT AB. It is shown in Table 4 and Figure 2. Drug release for both the test product and the reference product were found to be satisfactory.
  • Table 4 Summary of Dissolution Results of Macitentan 10 mg Film Tablet (Test Product) in Comparison to Opsumit 10 mg Film Tablet (Reference Product) in acetat buffer pH 4.5 with % 0.1 CTAB.
  • Figure 2 Comparative Dissolution Profiles of Opsumit 10 mg Film Tablet and Macitentan 10 mg Film Tablet (Test Product) in in acetat buffer pH 4.5 with % 0.1 CTAB.
  • the dissolution test has been performed for Opsumit 10 mg Film Tablet and Macitentan 10 mg Film Tablet (Test Product) in phosphate buffer pH 6.8 with 0,1% CTAB. It is shown in Table 5 and Figure 3. Drug release for both the test product and the reference product were found to be satisfactory.
  • Table 5 Summary of Dissolution Results of Macitentan 10 mg Film Tablet (Test Product) in Comparison to Opsumit 10 mg Film Tablet (Reference Product) in phosphate buffer pH 6.8 with 0,1% CTAB.
  • Figure 3 Comparative Dissolution Profiles of Opsumit 10 mg Film Tablet and Macitentan 10 mg Film Tablet (Test Product) in phosphate buffer pH 6.8 with 0,1% CTAB.
  • Stage 1 Sieving and Mixing Sieving and mixing macitentan, lactose monohydrate, microcrystalline cellulose and
  • Figure 1 Comparative Dissolution Profiles of Opsumit 10 mg Film Tablet and Macitentan 10 mg Film Tablet (Test Product) pH 1.2 with 0,1 HCL + 0,1% CT AB
  • Figure 2 Comparative Dissolution Profiles of Opsumit 10 mg Film Tablet and Macitentan 10 mg Film Tablet (Test Product) in in acetate buffer pH 4.5 with % 0.1 CTAB

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to the preparation of pharmaceutical compositions comprising macitentan is indicated for the treatment of pulmonary arterial hypertension (PAH), having a specific weight ratio of binder to disintegrant in formulation.

Description

PHARMACEUTICAL COMPOSITIONS COMPRISING MACITENTAN AS ACTIVE INGREDIENT AND OTHER RELEVANT EXCIPIENTS
Field of invention
The present invention relates to the preparation of pharmaceutical compositions comprising macitentan is indicated for the treatment of pulmonary arterial hypertension (PAH), having a specific ratio of binder to disintegrant in formulation.
Background of the invention
Macitentan has a chemical name as 5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2- yl)oxyethoxy]-N-(propylsulfamoyl)pyrimidin-4-amine and its chemical structure is shown in the Figure I. Macitentan has molecular weight of 588,3 g/mol, white or off-white Solid, crystalline powder.
Figure imgf000002_0001
Figure 1
Macitentan has been used as an orphan drug in the EU with the name of Opsumit and also in United States, is indicated for patients with pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) is a condition where there is high blood pressure in the arteries that supply the lungs. Pulmonary arterial hypertension (PAH) is also associated with a number of other medical diseases such as cirrhosis and connective tissue diseases like scleroderma.
EP1928409B relates to a pharmaceutical composition comprising macitentan and specific formulation excipients with lactose monohydrate, microcrystalline cellulose, polyvinylpyrrolidone, sodium starch glycolate, a surfactant (polysorbate) and a lubricant.
One of the oral administration way used commonly is tablet form. Tablet form has many advantages like cost-effective, lighter and compact, easiest and cheapest to package, can be masked by coating technique and greatest chemical and microbial stability over all oral dosage forms. A pharmaceutical composition may comprise one or more pharmaceutically acceptable excipient(s). Pharmaceutically acceptable excipients examples can be filler, disintegrant, binder, surfactant, lubricant, solvent, antiadherent, flavor, glidant, preservative, sweetener, suspending/viscosity agent, diluent, colorant and the mixtures thereof.
Ideal pharmaceutical excipient profile should have suitable physical and chemical properties with active ingredient and also other raw materials. These properties can be stable and reproducible, no unwanted interaction with active ingredient, inert property, desired functionality and cost effective.
One of the critical excipient for oral formulation such as tablet is binder in a pharmaceutical composition. Binders can be used for tablets that can provide the required mechanical strength, and also volume for low active dose tablets.
Another critical excipient for oral formulation such as tablet is disintegrant in a pharmaceutical composition. It is also known as disintegrating agents or disintegrators. Disintegrating agents are the substances which are added to an oral solid dosage to promote its rapid disintegration or break down into small particles after administration for facilitating rapid dissolution. Disintegrating agents are added to an oral solid dosage form to get quick drug release. Disintegrants are used to control the disintegration time for oral solid dosage forms such as tablets, capsules and the others as per pharmacopoeia.
Disintegrants can be classified into two groups, traditional and Super Disintegrants. Examples for traditional disintegrants: starch, sodium alginate etc. Examples for Super Disintegrants: crospovidone, croscarmellose sodium, sodium starch glycolate etc.
Summary of the invention
The present invention relates to the preparation of pharmaceutical compositions comprising macitentan, and one or more pharmaceutically acceptable excipients comprising a binder and a disintegrant with a specific ratio.
In this invention, a pharmaceutical composition comprising macitentan or pharmaceutically acceptable salts thereof, a disintegrant, a binder and optionally one or more pharmaceutically acceptable excipients, wherein the weight ratio of the binder to the disintegrant is from 0,55 to 0,72.
Detailed description of the invention
The present invention relates to preperation of pharmaceutical compositions comprising macitentan in the treatment of pulmonary arterial hypertension.
The present invention provides a pharmaceutical composition comprising macitentan for the treatment of pulmonary arterial hypertension, wherein process including wet granulation method. The present invention relates to the preparation of pharmaceutical compositions comprising macitentan or pharmaceutically acceptable salts or esters thereof, and one or more pharmaceutically acceptable carriers or excipients.
The present invention relates to the preparation of pharmaceutical compositions comprising macitentan, and one or more pharmaceutically acceptable carriers or excipients, comprising a binder and a disintegrant with a specific weight ratio.
The present invention relates to the preperation of pharmaceutical compositions comprising macitentan, and one or more pharmaceutically acceptable carriers or excipients, including a binder with a specific interval by tablet weight.
The present invention relates to the preperation of pharmaceutical compositions comprising macitentan, and one or more pharmaceutically acceptable carriers or excipients, including a disintegrant with a specific interval by tablet weight.
In this invention, a pharmaceutical composition comprising macitentan or pharmaceutically acceptable salts thereof, a disintegrant, a binder and optionally one or more pharmaceutically acceptable excipients, wherein the weight ratio of the binder to the disintegrant is from 0,55 to 0,72.
In this invention, it is obtained pharmaceutical compositions comprising macitentan and a disintegrant selected from a list consisting of: crospovidone, sodium starch glycolate and croscarmellose sodium or mixture thereof.
In this invention, it is obtained pharmaceutical compositions comprising macitentan and a disintegrant at a concentration of from 2% to 4% (w/w).
In this invention, it is obtained pharmaceutical compositions comprising macitentan and a binder having a concentration of from 1% to 3% (w/w).
According to a preferred embodiment of this invention, the pharmaceutical composition can be in the form of a tablet.
In this invention, target properties of tablet dosage forms is below:
■ Tablet should have elegant product without any cracks, discoloration or contamination.
■ Mechanical stregnth should be sufficient for production packaging, shipping and dispensing.
■ Physical properties shoul maintain the chemical and physical stability.
■ Tablet form should have predictable and reproducible manner for releasing the active ingredients. In preformulation studies for developing tablet dosage form, physicomechanical properties are determined such as particle size, tap density, crystalline form, compressibility, photomicrographs, melting point, taste, color, appearance, and viscosity. These properties has an important role in powder flow and compaction in tablet manufacturing process.
Dissolution test values for pharmaceutical compositions are one of the essential parameters for process development and solid dosage manufacturing.
Generally, excipients that is used in tablet dosage form are diluent, binder, disintegrants, lubricant, glidant, colouring agent, flavoring agent, sweetening agent and solvent except active ingredient.
In this invention, it is obtained pharmaceutical compositions comprising macitentan and a disintegrant at a concentration of from 2% to 4% (w/w).
In this invention, the ratio of disintegrants used to tablet weight is between 2%-4%. The composition comprises a disintegrant at the concentration of 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.4, 3.6, 3.8 and 4.0% (w/w). The most preferred amount in this range is 3.0%.
In this invention, the ratio of binder used to the total weight is between 1% - 3%. The composition comprises binder at the concentration of 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, 2.6, 2.8 and 3.0% (w/w). The most preferred amount in this range is 2.0%.
In this invention, manufacturing process generally consisting of four stages: a) Sieving and mixing, b) Wet Granulation, c) Mixing granule with external excipients, d) Tablet compression and Film Coating.
According to this invention, the amount of coating material by weight will be from 2 to 6%, preferably from 3 to 5% and more preferably from 3.5 to 4.5% of the weight of the tablet before its coating.
In this invention, disintegrant and binder are very critical. Disintegrant and binder should be selected with given ratio and properties.
There is a comparison table about test product and the others. Comparison table for our test product, which is the subject of the invention, with the formulation rates specified in the EP 1928409 patent and the opsumit components described in Table 1.
Table 1: Comparison table for relevant excipients of Macitentan lOmg Tablet (Test product), excipients on EP 1928409 examples and excipients of Opsumit product in Russia market.
Figure imgf000005_0001
Figure imgf000006_0001
In this invention, the main point is that the weight ratio of the binder to disintegrant in tablet composition comprising macitentan. When other relevant publications and open sources are evaluated, the originality and novelty of the subject can be seen. Above table supports this situation.
The stability of the pharmaceutical composition may be tested in conventional manner, e.g. by measurement of macitentan and its degradation products, dissolution, friability, disintegration time, appearance and/or microscopy, e.g. after storage at 25 °C and 60% relative humidity, and/or storage at 40°C and 75% relative humidity for defined periods of time.
In this invention, the formulations preferably contain active ingredient, filler, disintegrant, binder, surfactant, lubricant and solvent.
In this invention, tablets may also be produced. The tablets may vary in shape and be, for example, round, oval, oblong, cylindrical, clover-shaped or any other suitable shape.
The term “w/w%” as used herein, and as conventionally used in the pharmaceutical industry, refers to a percentage by weight compared to the total weight of the composition considered.
A pharmaceutical composition according to the invention is considered "stable", if during a certain period of time 70%, preferably 80% and most preferably 95% of the initial content of macitentan, is maintained over said period of time.
The term "treatment" or "treating" means any treatment of a disease or condition in a subject, such as a mammal, including: 1) preventing or protecting against the disease or condition, that is, causing the clinical symptoms not to develop; 2) inhibiting the disease or condition, that is, arresting or suppressing the development of clinical symptoms; and/or 3) relieving the disease or condition that is, causing the regression of clinical symptoms.
In this invention, the term "pulmonary hypertension" will be understood to include “a condition where there is high blood pressure in the arteries that supply the lungs”, including Subdivisions of Pulmonary Arterial Hypertension and World Health Organization classifications for Pulmonary Hypertension (PH).
Wet granulation is the most widely used process of granulation in the pharmaceutical industry. Wet granulation process can be very simple or very complex depending on the characteristics of the powders and the available equipments. Basicly, wet granulation method involves addition of a liquid solution (with or without binder) to powders, to form a wet mass or it forms granules by adding the powder together with an adhesive, instead of by compaction. Then, drying process starts and then sized to obtained granules with desired mesh. The granulate may then be tabletted /compressed, or other excipients may be added prior to tableting with suitable excipients.
The term "oral solid dosage form" as used herein denotes solid preparations (e.g. tablets) for oral administration each containing a single dose of one or more active substances.
Pharmaceutical composition of the present inventions may comprise one or more pharmaceutically acceptable excipient(s). Pharmaceutically acceptable excipients comprise, but are not limited to, filler, disintegrant, binder, surfactant, lubricant, solvent and the mixtures thereof, to facilitate the physical formulation of various dosage forms for oral administration like tablets.
As used herein, “pharmaceutically acceptable salt” refers to a salt of a compound that does not abrogate the biological activity and properties ofthe compound. Pharmaceutical salts can be obtained by reaction of a compound disclosed herein with an acid or base.
Suitable disintegrants according to the present invention include, but are not limited to, carboxymethylcellulose calcium, carboxymethylcellulose sodium, croscarmellose (crosslinked carboxymethylcellulose) sodium, cross-linked polyvinylpyrrolidone, crospovidone (crosslinked povidone, a synthetic cross-linked homopolymer of N-vinyl-2-pyrrolidone), alginic acid, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, polacrillin potassium, sodium alginate, sodium starch glycolate, partially hydrolysed starch, sodium carboxymethyl starch, and starch. The preferred disintegrant is crospovidone.
Suitable binders according to the present invention include, but are not limited to, hydroxypropyl cellulose, hypromellose (hydroxypropyl methylcellulose, HPMC), HPMC E5, acacia, alginic acid, carboxymethylcellulose, methylcellulose, hydroxyethylcellulose, ethylhydroxyethylcellulose, carboxymethylcellulose sodium, methylcellulose, polyvinyl pyrrolidone and pregelatinized starch. The preferred binder is Povidon K30.
Suitable lubricants according to the present invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, stearic acid, fumaric acid, sodium stearylfumarate, zinc stearate and polyethylene glycol. The preferred lubricant is magnesium stearate.
Suitable fillers according to the present invention include, but are not limited to, dibasic calcium phosphate, kaolin, microcrystalline cellulose, silicated microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, magnesium trisilicate, lactose such as example the anhydrous form or the hydrate form such as the monohydrate form, sugars such as dextrose, maltose, saccharose, glucose, fructose or maltodextrine, sugar alcohols such as mannitol, maltitol, sorbitol, xylitol, powdered cellulose, precipitated calcium carbonate, sodium carbonate, sodium phosphate and starch. Fillers which are slightly hygroscopic or non- hygroscopic are preferred, with non-hygroscopic fillers being particularly preferred, in particular when the dosage form is to be used for tropical countries. The preferred filler is microcrystalline cellulose.
Suitable surfactants and wetting agents according to the present invention include, but are not limited to, heptadecaethylene oxycetanol, lecithins, sorbitol monooleate, polyoxyethylene sorbitol monooleate, polyoxyethylene stearate, polyoxyethylen sorbitan monolaurate, benzalkonium chloride, nonoxynol 10, oxtoxynol 9, polysorbates, for example polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 80, sorbitan monopalmitate, sodium salts of fatty alcoholsulfates such as sodium lauryl sulfate, sodium dodecylsulfate, sodium salts of sulfosuccinates such as sodium dioctylsulfosuccinate, partially esters of fatty acids with alcohols such as glycerine monostearate, partially esters of fatty acids with sorbitans such as sorbitan monolaurate, partially esters of fatty acids with polyhydroxyethylene sorbitans such as polyethyleneglycol sorbitan monolaurate, - monostearate or -monooleate, ethers of fatty alcohols with polyhydroxyethylene, esters of fatty acids with polyhydroxyethylene, copolymers of ethylenoxide and propylenoxide (Pluronic®) and ethoxylated triglycerides. The preferred surfactant is polysorbate 80.
Suitable film-forming agents and coating materials according to the present invention include, but are not limited to, liquid glucose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (hypromellose, HPMC), methylcellulose, ethylcellulose, cellulose acetate phthalate, shellac, polyvinylpyrrolidone, copolymers of vinylpyrrolidone and vinylacetate such as Kollidon® VA64 BASF, copolymers of acrylic and/or methacrylic acid esters with trimethylammoniummethylacrylate, copolymers of dimethylaminomethacrylic acid and neutral methacrylic acid esters, polymers of methacrylic acid or methacrylic acid esters, copolymers of acrylic acid ethylester and methacrylic acid methyl ester, and copolymers of acrylic acid and acrylic acid methylester.
Solvents can be selected from the group, but not limited to, ethanol, ethyl alcohol, polyethylene glycol, propylene glycol, isopropyl alcohol, purified water and other materials known to one of ordinary skill in the art and mixtures thereof. The preferred solvent is purified water.
The present invention is described in the following example in more details. This example is not limiting the scope of the present invention and is to be considered under the light of the foregoing detailed description.
In this invention, dissolution tests has been performed to compare Opsumit 10 mg Film coated tablet (Reference product) and Macitentan 10 mg Film Tablet (Test product). The results have been compared to the reference product Opsumit 10 mg Film coated tablet and Macitentan 10 mg Film Tablet (Test Product). Relevant figures for Reference product / Test product are shown in Figure 1-3. Advantages
It is obtained optimum value for pharmaceutical composition comprising macitentan that is well ratio for tablet dosage form by using binder and disintegrant as excipients.
When the physical and chemical test results of the pharmaceutical composition obtained by using a specific ratio of binder and disintegrant are evaluated, it has been observed that it has positive effect on the manufacturing process.
It effects on many specifications during determining and designing manufacturing process for pharmaceutical products.
The pharmaceutical compositions of the invention are particularly suited for the oral administration.
The pharmaceutical compositions of the invention are particularly shows similar property in the stability and dissolution, it is extremely useful as a pharmaceutical product preparation technique.
The present invention provides pharmaceutical composition comprising macitentan and relevant excipients, characterized by i) A simple and exclusive manufacturing process ii) Stable formulation
Tablet dosage form is simple, cost-effective, easy and convenient to use, so it has high patient compliance.
The advantages of wet granulation method:
• Improving flow property and compression characteristics and increases density of granules
• Better distribution of color and soluble drugs if added in the binding solution.
• Reducing dust hazards
• Preventing segregation of powders
The compositions of the invention are advantageously in the form of unit dose. Preferably, each unit dose according to the invention comprises 1 to 100 mg, e.g. 5 to 50 mg, advantageously 8 to 20 mg, e.g. about 10 mg according to the invention, advantageously in combination with standard excipients and additives well known to one skilled in the field.
In present invention, tablet containing a binder shows similar dissolution property and by the addition of it, the drug dissolution property could be easily controlled.
Dissolution Tests
In this invention, dissolution testing has been performed in pH 1,2 (0,1 HCI + 0.1% cetyltrimethylammonium bromide (CTAB)), acetate buffer pH 4,5 (0,1% CTAB), phosphate buffer pH 6,8 (0,1% CTAB). General properties of relevant batches are shown in Table 2. The results have been compared to the reference product Opsumit 10 mg Film coated tablet and Macitentan 10 mg Film Tablet (Test Product).
Table 2: Summary of Batches used in In Vitro Dissolution Tests
Figure imgf000010_0001
In this invention, the dissolution test has been performed for Opsumit 10 mg FTB and Macitentan 10 mg Tablet (Test Product) pH 1.2 with 0,1 HCL + % 0,1 CT AB. It is shown in Table 3 and Figure 1. Drug release for both the test product and the reference product were found to be satisfactory.
Table 3: Summary of Dissolution Results of Macitentan 10 mg Film tablet (Test Product) in Comparison to Opsumit 10 mg FTB (Reference Product) in pH 1.2 with 0,1 HCL + 0,1% CTAB.
Figure imgf000010_0002
Figure imgf000011_0002
Figure 1: Comparative Dissolution Profiles of Opsumit 10 mg Film Tablet and Macitentan 10 mg Film Tablet (Test Product) pH 1.2 with 0,1 HCL + 0,1% CTAB.
In this invention, the dissolution test has been performed for Opsumit 10 mg Film Tablet and Macitentan 10 mg Film Tablet (Test Product) in acetat buffer pH 4.5 with 0.1% CT AB. It is shown in Table 4 and Figure 2. Drug release for both the test product and the reference product were found to be satisfactory.
Table 4: Summary of Dissolution Results of Macitentan 10 mg Film Tablet (Test Product) in Comparison to Opsumit 10 mg Film Tablet (Reference Product) in acetat buffer pH 4.5 with % 0.1 CTAB.
Figure imgf000011_0001
Figure imgf000012_0002
Figure 2: Comparative Dissolution Profiles of Opsumit 10 mg Film Tablet and Macitentan 10 mg Film Tablet (Test Product) in in acetat buffer pH 4.5 with % 0.1 CTAB.
In this invention, the dissolution test has been performed for Opsumit 10 mg Film Tablet and Macitentan 10 mg Film Tablet (Test Product) in phosphate buffer pH 6.8 with 0,1% CTAB. It is shown in Table 5 and Figure 3. Drug release for both the test product and the reference product were found to be satisfactory.
Table 5: Summary of Dissolution Results of Macitentan 10 mg Film Tablet (Test Product) in Comparison to Opsumit 10 mg Film Tablet (Reference Product) in phosphate buffer pH 6.8 with 0,1% CTAB.
Figure imgf000012_0001
Figure imgf000013_0002
Figure 3: Comparative Dissolution Profiles of Opsumit 10 mg Film Tablet and Macitentan 10 mg Film Tablet (Test Product) in phosphate buffer pH 6.8 with 0,1% CTAB.
Overall conclusion for dissolution results:
In-vitro comparative dissolution data and profiles has been demonstrated above in pH 1.2, pH 4.5, pH 6.8. All the multi media profiles were comparatively similar to that of the selected Reference product Opsumit 10 mg Film Tablet. Example 1: Macitentan lOmg uncoated tablet unit formula
Figure imgf000013_0001
The process for the preparation of Macitentan lOmg uncoated tablet according to the present invention can be carried out according to the following process:
1. Stage 1 Sieving and Mixing Sieving and mixing: macitentan, lactose monohydrate, microcrystalline cellulose and
Povidone K30.
12 2. Stage 2 Wet Granulation
Wet granulation was done with purified water which contains polysorbate 80 into it.
3. Stage 3 Sieving and Mixing
Dried granules were sieved and mixed with crospovidone, magnesium stearate
4. Stage 4 Tablet compression and Film Coating
Tablet compression and Film Coating
Brief description of the figures included in the description:
Figure 1: Comparative Dissolution Profiles of Opsumit 10 mg Film Tablet and Macitentan 10 mg Film Tablet (Test Product) pH 1.2 with 0,1 HCL + 0,1% CT AB
Figure 2: Comparative Dissolution Profiles of Opsumit 10 mg Film Tablet and Macitentan 10 mg Film Tablet (Test Product) in in acetate buffer pH 4.5 with % 0.1 CTAB
Figure 3: Comparative Dissolution Profiles of Opsumit 10 mg Film Tablet and Macitentan 10 mg Film Tablet (Test Product) in phosphate buffer pH 6.8 with 0,1% CTAB

Claims

1. A pharmaceutical composition comprising macitentan or pharmaceutically acceptable salts thereof, a disintegrant, a binder and optionally one or more pharmaceutically acceptable excipient, wherein the weight ratio of the binder to the disintegrant is from 0,55 to 0,72.
2. The pharmaceutical composition according to claim 1, wherein the weight ratio of the binder to the disintegrant is from 0,58 to 0,70, preferably from 0.60 to 0.65.
3. The pharmaceutical composition according to any proceeding claims, wherein the disintegrant is selected from crospovidone, sodium starch glycolate, croscarmellose sodium or mixtures thereof.
4. The pharmaceutical composition according to any proceeding claims, wherein the binder comprises povidone, hydroxypropyly methylcellulose (HPMC), hydroxypropylcellulose (HPC) or mixtures thereof.
5. The pharmaceutical composition according to any proceeding claims, wherein one or more pharmaceutically acceptable excipient is selected from filler, surfactant and lubricant.
6. The pharmaceutical composition according to any proceeding claims, wherein the composition is an oral solid dosage form, preferably a tablet.
7. The pharmaceutical composition according to claim 6, wherein the composition is a film coated tablet.
PCT/TR2021/051618 2021-12-30 2021-12-30 Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients WO2023128898A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP21970145.5A EP4456983A1 (en) 2021-12-30 2021-12-30 Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients
PCT/TR2021/051618 WO2023128898A1 (en) 2021-12-30 2021-12-30 Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2021/051618 WO2023128898A1 (en) 2021-12-30 2021-12-30 Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients

Publications (1)

Publication Number Publication Date
WO2023128898A1 true WO2023128898A1 (en) 2023-07-06

Family

ID=87000088

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2021/051618 WO2023128898A1 (en) 2021-12-30 2021-12-30 Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients

Country Status (2)

Country Link
EP (1) EP4456983A1 (en)
WO (1) WO2023128898A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109260163A (en) * 2018-10-07 2019-01-25 威海云睿信息科技有限公司 A kind of macitentan tablet composition
WO2021005478A1 (en) * 2019-07-05 2021-01-14 TECNIMEDE - Sociedade Técnico-medicinal, SA Compressed macitentan compositions, methods and uses thereof
CN112336693A (en) * 2020-09-29 2021-02-09 南京斯泰尔医药科技有限公司 Method for rapidly controlling and evaluating release of macitentan tablets

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109260163A (en) * 2018-10-07 2019-01-25 威海云睿信息科技有限公司 A kind of macitentan tablet composition
WO2021005478A1 (en) * 2019-07-05 2021-01-14 TECNIMEDE - Sociedade Técnico-medicinal, SA Compressed macitentan compositions, methods and uses thereof
CN112336693A (en) * 2020-09-29 2021-02-09 南京斯泰尔医药科技有限公司 Method for rapidly controlling and evaluating release of macitentan tablets

Also Published As

Publication number Publication date
EP4456983A1 (en) 2024-11-06

Similar Documents

Publication Publication Date Title
ES2535478T3 (en) Pharmaceutical composition
RU2744432C2 (en) Pharmaceutical composition including janus kinase inhibitor or pharmaceutically acceptable salt thereof
EP3086781B1 (en) Pharmaceutical composition of dpp-iv inhibitor in combination with metformin
KR102072546B1 (en) Oral tablet formulation of lenalidomide
TWI228414B (en) Pharmaceutical composition comprising carvedilol and hydrochlorothiazide, solid dosage form comprising it, and process for the production of the same
JPH0251402B2 (en)
CA2621273A1 (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
KR20070027560A (en) Coated tablet formulation and method
JP2010522692A (en) Solid pharmaceutical composition containing a benzimidazole-7-carboxylate derivative and a pH adjuster
JP5417662B2 (en) Nevirapine sustained release formulation
WO2014125352A1 (en) Pharmaceutical compositions comprising tadalafil
WO2022177983A1 (en) Pharmaceutical compositions of cabozantinib
EP3184103A1 (en) Pharmaceutical composition comprising atorvastatin or a salt thereof
ES2901598T3 (en) Film-coated tablet having high chemical stability of the active ingredient
EP4456983A1 (en) Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients
JP2023036924A (en) Pharmaceutical composition containing lenalidomide
US20090269409A1 (en) Pharmaceutical compositions comprising eszopiclone
WO2020111089A1 (en) Pharmaceutical composition
JP2009538905A (en) Stable formulation comprising moisture sensitive drug and method for producing the same
WO2020122244A1 (en) Tablet and method for producing same
CN116490178A (en) Composition of SGLT-2 inhibitor and angiotensin receptor blocker and application
TR2024008321T2 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING MACITENTAN AS ACTIVE INGREDIENT AND OTHER RELATED EXCIPIENTS
WO2005030219A1 (en) Method of stabilizing diarylvinylene compound
KR20200015758A (en) Pharmaceutical composition
WO2014096983A1 (en) Stable pharmaceutical compositions of saxagliptin or salts thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21970145

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2024/008321

Country of ref document: TR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021970145

Country of ref document: EP

Effective date: 20240730